Under the contract, Median will employ its LMS platform at all 65 investigator and independent review sites.
The aim of the project is to reduce reading variability and discordance issues in image interpretation, which are thought to impact clinical trial outcomes.
Using Median LMS, the sites will be able to conduct RECIST 1.1 criteria-based evaluations, while the end-to-end image management will be carried out through Median CTIS.
The real-time electronic imaging data transfer from investigator sites to independent review sites will allow the independent reviews to be processed faster and with a more efficient management of queries on missing or erroneous data.
Median Technologies Business Development vice president Jerome Windsor said their solutions increase the accuracy of data interpretation and also create new perspectives for pathology follow up, benefiting the patients.